Celcuity Inc. Common Stock
CELCStock
$88.29+564.08%52W
Market Cap$4.29B
P/E—
Div yield—
Beta0.19
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-25.64%
Price vs S&P 500 (4W)4.20%
VGM Score63.37
Market Capitalization$4.29B
Earnings Surprise History
Q1 26-0.97est. -1.07
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.29
4.28
4.33
4.33
Industry Peers — Health Services(29)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CELCCelcuity Inc. Common Stock | — | — | B | $88.29 |
| NTRANatera, Inc. Common Stock | F | A | B | $269.83 |
| DGXQuest Diagnostics Inc. | C | D | C | $209.41 |
| LHLabcorp Holdings Inc. | C | D | C | $281.94 |
| GHGuardant Health, Inc. Common Stock | F | A | A | $155.00 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | B | $128.18 |
| RDNTRadNet, Inc. Common Stock | D | C | C | $62.99 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | D | $16.48 |
| VCYTVeracyte, Inc. | D | A | A | $59.22 |
| GRALGRAIL, Inc. Common Stock | D | A | B | $71.96 |
About
Celcuity is a clinical-stage oncology biotechnology company developing gedatolisib, a dual PI3K/mTOR inhibitor with a differentiated mechanism of action compared to existing therapies. The company's lead program is in Phase 3 development (VIKTORIA-1), evaluating gedatolisib combined with fulvestrant with or without palbociclib for hormone receptor-positive, HER2-negative advanced breast cancer.